Oral Cyclophosphamide for the Management of Hormone-refractory Prostate Cancer
| Autor: | W. Hunter Watt, J. J. Grygiel, G. J. Coorey, Edward McNeil, K. Cox, John M. Rogers, Derek Raghavan, A. S. Coates, B. S. Pearson |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Male
Oncology medicine.medical_specialty Cyclophosphamide Urology medicine.medical_treatment Administration Oral Disease Drug Administration Schedule Prostate cancer Prostate Oral administration Internal medicine medicine Humans Antineoplastic Agents Alkylating Aged Chemotherapy business.industry Prostatic Neoplasms Cancer Middle Aged medicine.disease Surgery Clinical trial medicine.anatomical_structure business medicine.drug |
| Zdroj: | British Journal of Urology. 72:625-628 |
| ISSN: | 1464-410X 0007-1331 |
| DOI: | 10.1111/j.1464-410x.1993.tb16222.x |
| Popis: | Summary Thirty patients with hormone-refractory prostate cancer were treated with cycles of oral cyclophosphamide (100 mg/m2/dayfor 14 days, with a 14-day gap). Eighteen patients had a significant improvement in symptoms of advanced disease, 6 had objective partial remissions and 13 had stabilisation of disease (criteria of National Prostatic Cancer Project). The median survival from the time of diagnosis was 33.3 months, and from the commencement of cyclophosphamide 12.7 months. The treatment was well tolerated. Oral cyclophosphamide is active in the treatment of advanced hormone-refractory prostate cancer and yields symptomatic and objective remissions without undue side effects. This observation requires validation, with further testing of its impact on survival in randomised clinical trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text